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Predilution hemodiafiltration displays no hemodynamic advan-
tage over low-flux hemodialysis under matched conditions.
Background. It is the prevailing view that convective dialysis
techniques stabilize blood pressure. The aim of this study was
to compare the intrasession hemodynamics during high-dose
predilution hemodiafiltration (HDF) and low-flux hemodialsis,
under strict controlled conditions.
Methods. Twelve stable hemodialysis patients were investi-
gated in a randomized crossover blinded controlled trial. The
patients were allocated to one session of predilution HDF (sub-
stitution fluid 1.20 ± 0.10 L/kg body weight) and one session
of hemodialysis at 4 12 hours. To eliminate confounding factors,
dialysis dose, ultrafiltration volume and arterial temperature
were matched. At the start of the dialysis the patients’ core
temperature was “locked” by an automatic feedback system
regulating the dialysate temperature; thereby, patients’ tem-
perature was kept stable throughout the whole treatment. The
calcium-ion concentration in the substitution/dialysis fluid was
1.25 mmol/L. Cardiac output was measured hourly by the ultra-
sound velocity dilution method.
Results. Mean blood pressure, cardiac output, stroke volume,
cardiac work, and relative blood volume was significantly re-
duced in both treatments. Total peripheral resistance increased
significantly in both groups. Ultrafiltration volume, cardiopul-
monary recirculation, Kt/V, and total energy transfer were
similar for hemodialysis and HDF. The pulse rate showed no
significant change throughout both sessions. No significant dif-
ferences were revealed between hemodialysis and HDF.
Conclusion. The hemodynamics of predilution HDF and low-
flux hemodialysis displayed a similar profile during matched
conditions. An acute circulatory benefit of convective solute
removal over diffusive could not be demonstrated.
Despite the extensive research on the pathophysiol-
ogy of dialysis-related hemodynamic instability and the
growing understanding of the contributing mechanisms,
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intradialytic circulatory instability remains a significant
cause of patient morbidity and mortality [1–4].
There is a general agreement on the multifactorial ori-
gin of hemodynamic instability during dialysis treatment
[1, 5–7]. Nevertheless, whenever attempting to compare
corresponding studies from the literature, one discovers
a discrepancy between published data, which may be par-
tially explained by the biologic heterogeneity of the dialy-
sis population and the numerous possible options regard-
ing the technical characteristics of the various artificial
kidney treatments. Furthermore, few comparative stud-
ies have matched for the possible confounding factors,
thereby making interpretation of dialysis-hemodynamic
published data difficult [8].
It has been the prevailing view for many years that con-
vective techniques alone, or in combination with dialysis,
display lower incidence of intradialytic hypotension com-
pared with the classic diffusive treatments [9–14]. How-
ever, the precise mechanisms involved are unclear and,
in addition, it is arguable if the proposed stabilizing ef-
fect of convective therapies on blood pressure is acute or
delayed [9, 12, 15].
The central role of temperature in the pathogenesis
of hypotension during dialysis was noted back on the
early 1980s [16–18] and there is now a substantial body
of research to support the theory that much of the ap-
parent dissimilarities between diffusive and convective
techniques could be explained by the different energy
transfer profiles (thermal energy dissipation in the extra-
corporeal circuit) displayed by the two treatment modal-
ities [2, 19–28]. Thereby, it became evident that control of
the energy exchange and temperature is essential in the
studies of intradialytic hemodynamic stability.
The use of hemofiltration has been unfavorable for
years due to the limited removal of small-molecular-
weight metabolites [29]. On-line predilution hemodiafil-
tration (pre-HDF) has overcome all the drawbacks of
the traditional hemofiltration [30, 31]. The importance
of control of the thermal energy exchange may be even
greater when pre-HDF is applied due to the large quan-
tity of fluid transport between the patient and the dialyzer
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during treatment. This can be accomplished with a blood
temperature monitor (BTM) device in the dialysis con-
sole that allows control of the thermal energy flux and
patient’s intradialytic temperature [32].
The aim of the present study was to investigate and
compare the hemodynamic changes between on-line
pre-HDF and conventional low-flux hemodialysis during
temperature controlled, dialysis dose, and ultrafiltration
volume–matched conditions in a controlled, blinded ran-
domized study.
METHODS
A blinded randomized controlled crossover design was
applied, with each patient serving as his/her own con-
trol, including one session of hemodialysis and HDF. The
patients were blinded with regard to the modality of treat-
ment. The study was conducted in two consecutive dialy-
sis sessions each preceded by two dialysis-free days. The
order of treatment was randomized.
Patients
Patients were recruited from the chronic hemodialy-
sis population from the department of renal medicine C,
Skejby sygehus, Aarhus University Hospital, Denmark.
Inclusion criteria were age >18 years, stable without se-
vere clinical symptoms of heart failure [New York Heart
Association (NYHA) class 0-II], regular (for at least
3 months) hemodialysis, HDF, or hemofiltration, three
times weekly, possibility to ultrafiltrate approximately
3% of the body weight during dialysis, hematocrit >30%,
and stable arteriovenous fistula.
Exclusion criteria were body dry weight >95 kg, in-
tradialytic adverse events or hypotensive episodes re-
quiring intervention in more than one dialysis session
within 4 weeks, diabetes mellitus, acute myocardial in-
farction within 3 months, angina pectoris, symptoms of
severe heart failure (NYHA class III-IV), cerebrovascu-
lar incident within three months, arterial hypertension
(diastolic blood pressure >110 mm Hg at the beginning
of dialysis, during the last 3 weeks), cardiac arrhythmia,
hemodynamic significant cardiac valve defect, noncom-
pliant fluid intake, predialysis plasma calcium-ion <1.05
or >1.40 mmol/L, infection, gastrointestinal hemorrhage,
pregnancy, severe illness such as malignancy, alcohol or
drug abuse, and noncompliance or unwillingness to fol-
low the protocol.
The study was performed in accordance with the
Helsinki II declaration and approval of the local ethical
committee. After obtaining informed consent 12 patients
(females/males=4/8) with age (mean±SD) 54±13 years
(range 30 to 71 years), body weight 70 ± 13 kg (range 48
to 91 kg), height 170 ± 9 cm and time on renal replace-
ment 7 ± 7 years (range 0.5 to 20 years), were included.
Six patients received antihypertensive medication: an-
giotensin receptor antagonist (N = 1), calcium channel
blocker (N = 1), beta blocker (N = 2), beta blocker +
angiotensin receptor antagonist (N = 1), beta blocker +
calcium channel blocker (N = 1). The original renal dis-
ease was chronic glomerulonephritis (N = 3), polycystic
kidney disease (N = 2), prune belly syndrome (N = 1),
nephrosclerosis (N = 2), reflux nephropathy (N = 1),
undetermined cause of end-stage renal disease (ESRD)
(N = 2), and analgesic nephropathy (N = 1). Treatment
modality before inclusion in the study was hemofiltra-
tion predilution (N = 3), post-HDF (N = 1), and low-flux
hemodialysis (N = 8).
Hemodialysis and HDF prescription
Dialysis console was Fresenius 4008H (Fresenius Medi-
cal Care, Bad Homburg, Germany). Filters were high-flux
HdF100 S to HDF and low-flux F8 HPS to hemodialysis
(Fresenius Medical Care). The treatment modality was
blinded to the patient by use of filter types not known to
the patients and not ordinarily used in the department.
The tubing was mounted as to HDF in all sessions and the
indicators showing the treatment modality on the con-
sole were covered. All sessions in the study had dura-
tion of 41/2 hours per session. The dialysate and infusate
(substitution fluid) had identical composition (mmol/L):
Sodium close to patients’ usual serum sodium at dialysis
start (138 ± 2), potassium, 2; chloride, 106; bicarbonate,
36; acetate, 3; magnesium, 0.5; glucose, 6; and calcium-ion,
1.25. Ultrafiltration rate and sodium concentration were
fixed during each session. The infusate was prepared on-
line by the dialysis machine.
The patients were instructed to achieve a predialysis
weight close to 3% more than their usual “end of dial-
ysis weight” (EDW) by adjustments of fluid intake. The
EDW was determined prior to the study based on the
usual clinical standard of the department. The ultrafil-
tration volume per study session was adjusted to reach
the defined EDW. An extra ultrafiltration of 300 mL was
added to compensate for saline injections used for the
cardiac output measurements (see below). The effective
dialyzer blood flow was adjusted individually to 1.3 ×
EDW (kg) ∗ 1000/270 mL/min in all sessions with a max-
imum of 350 mL/min. The final substitution fluid volume
was (mean ± SD) 1.20 ± 0.1 L/kg body weight/session
(total volume 83 ± 9 L/session). The infusate flow rate
in the HDF sessions was equal to the dialyser blood flow
rate. Dialysate flow was set to 500 mL/min on the console.
The patients were not allowed to eat, drink, or sleep dur-
ing the study sessions. All medications were continued
and administered as usual throughout the study.
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Blood pressure, pulse rate, and cardiac output
After insertion of the dialysis needles the patients were
allowed to rest for 10 minutes. After basal blood pressure
and pulse recordings, heparin was given and hemodial-
ysis or HDF was started according to the randomiza-
tion. Blood pressure and pulse rate were subsequently
recorded at 15-minute intervals during, and 10 minutes
after, dialysis by use of an automatic oscillometric blood
pressure monitor mounted as part of the dialysis console
(blood pressure module). The cardiac output was mea-
sured by ultrasound velocity dilution method, utilizing a
HD01 monitor [33] (Transonic Systems, Inc., Ithaca, NY,
USA). Measurements were performed in duplicate and if
results deviated more than 15% a third measurement was
done. The mean of the two closest recordings was noted
as the result. The cardiac output was measured at 15,
75, 135, 195, and 255 minutes. Total peripheral resistance
(TPR) was calculated as mean arterial pressure/cardiac
output and stroke volume as cardiac output/pulse rate.
The total cardiopulmonary recirculation was measured
by the blood temperature monitor (see below) within the
first and last hour of each session by use of the thermod-
ilution method. All hemodynamic measurements were
performed in the supine position with the head elevated
approximately 30 degrees. A standard cardiac echo scan
was done on a separate occasion with regard to left ven-
tricular performance and exclusion of hemodynamic sig-
nificant valvular disease.
Temperature and energy transfer
The temperature and energy transfer in the arterial (A-
tp) and venous (V-tp) blood lines were recorded continu-
ously by the blood temperature monitor module mounted
on the console. At the start of the dialysis the patients’
spontaneous core temperature at dialysis start (corre-
sponding to the temperature in the arterial blood line)
was “locked” by the blood temperature monitor device.
A procedure aimed to keep patients temperature sta-
ble throughout the whole treatment (isothermic dialysis).
Any subsequent alterations in the arterial temperature
were counteracted by the feedback loop (connecting the
arterial and venous blood temperature sensor with the
dialysate thermostat) by alterations of the temperature
in the dialysate and thereby the venous blood line.
Relative blood volume and ultrafiltration
Changes in the relative blood volume during treat-
ment were recorded by the module integrated in the
dialysis machine utilizing of continuous on-line measure-
ment of the total blood protein concentration (blood vol-
ume monitor). The cumulated ultrafiltration volume was
noted at 15-minute intervals.
Clinical chemistry and dialysis dose
Before and 10 minutes after dialyses, blood was drawn
from the arterial canula for determination of hemoglobin,
hematocrit, sodium, potassium, total carbon dioxide, al-
bumin, creatinine, urea, phosphorus, and calcium-ion.
The urea reduction ratio (URR) was calculated and the
dialytic Kt/V urea estimated by the Daugirdas formula.
Statistical calculations
Individual delta values (difference from start to end)
in each type of treatment were calculated. Data were an-
alyzed by use of paired or unpaired Student t test as ap-
propriate. (SPSS version 10.0.5, SPSS Inc., Chicago, IL,
USA). P < 0.05 was considered as significant. Data are
expressed as mean ± SE or mean ± SD (as noted).
RESULTS
Hemodynamic and thermal parameters are listed in
Table 1.
Blood pressure and pulse rate
The blood pressure decreased significantly during
hemodialysis throughout the treatment (Fig. 1): diastolic
blood pressure from 83 ± 3 to 77 ± 4 mm Hg (P < 0.01),
mean arterial presssure from 104 ± 4 to 94 ± 3 mm Hg
(P < 0.01), and systolic blood pressure from144 ± 6 mm
Hg to 129 ± 5 mm Hg (P < 0.01). In HDF the correspond-
ing values were diastolic blood pressure from 81 ± 3 to
73 ± 4 mm Hg (P < 0.01), mean arterial pressure from
103 ± 4 to 91 ± 5 mm Hg (P < 0.01), and systolic blood
pressure from 145 ± 7 mm Hg to 128 ± 8 mm Hg (P <
0.01). There were no significant differences between
hemodialysis and HDF. There were no episodes of sudden
hypotension in either treatment modality and no differ-
ences in the minimal mean arterial pressure during the
sessions. The pulse rate did not change significantly dur-
ing either on HDF or hemodialysis and there were no
significant differences between treatment modalities.
Cardiac output, stroke volume, and peripheral resistance
The cardiac output was reduced approximately 20%
during both types of treatment from 6.44 ± 0.40 to 5.22
± 0.44 L/min (P < 0.01) in HDF and from 6.63 ± 0.32
to 5.33 ± 0.36 L/min (P < 0.01) in hemodialysis (Fig. 2).
There was no significant difference between hemodialysis
and HDF. The stroke volume was also reduced approx-
imately 20% from 91 ± 6 to 70 ± 5 mL (P < 0.01) in
HDF vs. 91 ± 5 to 76 ± 4 mL in hemodialysis (P < 0.01)
(Fig. 3). There was no significant difference between the
treatment modalities. The total peripheral resistance in-
creased significantly in both groups from 16 ± 1 to 18 ±
1 mm Hg × min/L (P < 0.05) in HDF vs. 15 ± 1 to 18
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Table 1. Hemodynamic and thermal parameters
P (HDSTART P (HDFSTART P
HDSTART HDEND vs. HDEND) HDFSTART HDFEND vs. HDFEND) (HD vs. HDF)
Systolic blood pressure mm Hg 144 ± 6 129 ± 5 <0.01 145 ± 7 128 ± 8 <0.01 NS
Diastolic blood pressure mm Hg 83 ± 3 77 ± 4 <0.01 81 ± 3 73 ± 4 <0.01 NS
Mean arterial pressure mm Hg 104 ± 4 94 ± 3 <0.01 103 ± 4 91 ± 5 <0.01 NS
Pulse rate beats/min 72 ± 3 73 ± 3 NS 70 ± 3 74 ± 3 NS NS
Cardiac output L/min 6.6 ± 0.3 5.3 ± 0.3 <0.01 6.4 ± 0.4 5.2 ± 0.4 <0.01 NS
Stroke volume mL 91 ± 5 76 ± 4 <0.01 91 ± 6 70 ± 5 <0.01 NS
Total peripheral resistance 15 ± 1 18 ± 1 <0.01 16 ± 1 18 ± 1 <0.05 NS
mm Hg ∗ min/L
Cardiac work mm Hg ∗ L/min 918 ± 80 697 ± 71 <0.01 900 ± 76 673 ± 87 <0.01 NS
Relative blood volume% 90 ± 1.9 <0.01 89 ± 1.1 <0.05 NS
Ultrafiltration mL 3066 ± 276 2992 ± 256 NS
ATP ◦C 36.34 ± 0.07 36.65 ± 0.09 0.01 36.41 ± 0.12 36.60 ± 0.09 NS NS
VTP ◦C 36.38 ± 0.07 35.88 ± 0.28 NS 36.53 ± 0.1 35.87 ± 0.27 <0.05 NS
ATP-VTP ◦C −0.04 ± 0.1 0.78 ± 0.21 <0.01 −0.12 ± 0.12 0.73 ± 0.21 <0.01 NS
Total energy transfer kJ 155 ± 42 135 ± 39 NS
Recirculation% 6.3 ± 1 9.4 ± 0.6 <0.01 7.8 ± 1 9.7 ± 0.5 <0.01 NS
Abbreviations are: HDSTART, hemodialysis start; HDEND, hemodialysis end; HDFSTART, hemodiafiltration start; HDFEND, hemodiafiltration end; ATP, arterial
temperature; VTP, venous temperature. Values expressed as mean ± SEM.
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Fig. 1 Mean blood pressure. Abbreviations are: HDF, hemodiafiltra-
tion; HD, hemodialysis; pHD (P value HDSTART vs. HDEND); pHDF (P
value HDFSTART vs. HDFEND). All values mean ± SEM. P value (HD
vs. HDF) is NS. ∗P < 0.05; ∗∗P ≤ 0.01.
± 1 mm Hg ∗ min/L (P < 0.01) in hemodialysis (Fig. 4).
The cardiac work, calculated as cardiac output ∗ systolic
blood pressure, was reduced 27% during HDF and 24%
during hemodialysis treatment, from 900 ± 76 mm Hg ∗
L/min to 673 ± 87 mm Hg ∗ L/min (P < 0.01) in HDF
and 918 ± 80 mm Hg ∗ L/min to 697 ± 71 mm Hg ∗ L/min
in hemodialysis (P < 0.01). There were no differences
between the treatment modalities.
Relative blood volume and ultrafiltration
The mean relative blood volume declined linearly dur-
ing both treatments and was reduced to 89% ±1.1% (P <
0.05) in HDF vs. 90% ±1.9% (P < 0.01) in hemodialysis.
Ultrafiltration rate did not differ significantly between
groups at any time. The cumulated ultrafiltration vol-
ume was 3066 ± 276 mL in HDF vs. 2992 ± 256 mL in
hemodialysis.
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Fig. 2 Cardiac output. Abbreviations are: HDF, hemodiafiltration;
HD, hemodialysis; pHD (P value HDSTART vs. HDEND); pHDF (P value
HDFSTART vs. HDFEND). All values mean ± SEM. P value (HD vs.
HDF) is NS. ∗P < 0.05; ∗∗P ≤ 0.01.
Energy transfer and temperatures
The A-tp was kept constant within 0.09 ± 0.07◦C (NS)
in hemodialysis and 0.15 ± 0.13◦C (NS) in HDF between
the first and last cardiac output measurement at 15 and
255 minutes, respectively (Fig. 5). However, a small in-
crease of approximately 0.2◦C (NS) in HDF and 0.3◦C
(P < 0.05) in hemodialysis was observed within the first
15 to 45 minutes to a constant plateau for the rest of
both types of treatment, without significant differences
between groups at any time (Fig. 5). This was explained
by the time lag required for blood temperature monitor
equilibration at the initiation of the treatment.
The V-tp displayed higher variability compared with
the A-tp throughout both types of treatment (Fig. 6). The
V-tp dropped 0.50 ± 0.33◦C (P = 0.15) in hemodialysis
sessions and 0.66 ± 0.25◦C (P < 0.05) in HDF sessions.
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Fig. 3 Stroke volume (SV). Abbreviations are: HDF, hemodiafil-
tration; HD, hemodialysis; pHD (P value HDSTART vs. HDEND);
pHDF (P value HDFSTART vs. HDFEND). All values mean ± SEM.
P value (HD vs. HDF) is NS. ∗P < 0.05; ∗∗P ≤ 0.01.
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Fig. 4 Total peripheral resistance (TPR). Abbreviations are: HDF,
hemodiafiltration; HD, hemodialysis; pHD (P value HDSTART vs.
HDEND); pHDF (P value HDFSTART vs. HDFEND). All values mean
± SEM. P value (HD vs. HDF) is NS. ∗P < 0.05; ∗∗P ≤ 0.01.
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Fig. 5 Arterial temperature. Abbreviations are: HDF, hemodiafil-
tration; HD, hemodialysis; pHD (P value HDSTART vs. HDEND);
pHDF (P value HDFSTART vs. HDFEND). All values mean ± SEM.
P value (HD vs. HDF) is NS. ∗P < 0.05; ∗∗P ≤ 0.01.
The intratreatment AV-tp difference (at 270 minutes) was
0.73 ± 0.21◦C (P < 0.01) in HDF and 0.78 ± 0.21◦C
(P < 0.01) in hemodialysis, without significant differences
between the groups.
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Fig. 6 Venous temperature. Abbreviations are: HDF, hemodiafil-
tration; HD, hemodialysis; pHD (P value HDSTART vs. HDEND);
pHDF (P value HDFSTART vs. HDFEND). All values mean ± SEM.
P value (HD vs. HDF) is NS. ∗P < 0.05; ∗∗P ≤ 0.01.
The total energy transfer from patient to dialyzer was
155 ± 42 kJ in hemodialysis and 135 ± 39 kJ in HDF
(hemodialyssi vs. HDF, P value NS), according to ap-
proximately 13% of estimated resting energy expendure
(Harris-Benedict equation [34]).
Recirculation
The total cardiopulmonary recirculation was 7.8% ±
1% at start and 9.7% ± 0.5% at end in HDF and 6.3%
± 1% and 9.4% ± 0.6%, respectively, in hemodialysis,
without significant difference between the groups.
Clinical chemistry and dialysis dose
The data are shown in Table 2. In general, the changes
followed the same patterns in both treatment modalities
and no significant differences were observed. The dialysis
dose in the groups was closely matched according to urea
Kt/V 1.8 ± 0.2 in HDF and 1.7 ± 0.1 in hemodialysis.
DISCUSSION
This is, to our knowledge, the first study comparing
on-line high-dose pre-HDF and low-flux hemodialysis re-
garding their hemodynamic and thermal parameters on
the basis of strict controlled conditions. In order to elimi-
nate possible confounding factors, dialysis dose and ultra-
filtration volume were matched. Furthermore, by means
of the blood temperature monitor module, the dialysate
temperature was tailored to the arterial temperature, as
recorded at the beginning of every treatment, resulting in
stable body temperature throughout the whole session.
Under the above mentioned standardized conditions,
no significant inter-treatment differences were noted re-
garding blood pressure, cardiac output, TPR, pulse rate,
relative blood volume, and energy transfer. A signifi-
cant intratreatment reduction in blood pressure, cardiac
output, stroke volume, relative blood volume, and V-tp
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Table 2. Clinical chemistry
HDSTART HDEND HDFSTART HDFEND
Urea mmol/L 21.5 (4.5) 5.0 (1.4) 21.7 (5.9) 4.6 (1)
Creatinin lmol/L 914 (148) 308 (57) 907 (107) 302 (47)
Sodium mmol/L 136 (3) 139 (2) 135 (3) 138 (2)
Potassium mmol/L 4.6 (0.6) 3.3 (0.3) 4.6 (0.6) 3.3 (0.2)
Hematocrit % 38 (3) 41 (4) 37 (3) 42 (4)
Carbon dioxide 25.7 (2.1) 32.5 (1.8) 25.6 (2.7) 31.5 (1.5)
mmol/L
Phosphorus 1.45 (0.31) 0.76 (0.11) 1.48 (0.30) 0.66 (0.09)
mmol/L
Calcium-ion 1.21 (0.08) 1.19 (0.04) 1.21 (0.6) 1.17 (0.02)
mmol/L
Abbreviations are: HDSTART, hemodialysis start; HDEND, hemodialysis end;
HDFSTART, hemodiafiltration start; HDFEND, hemodiafiltration end. All values
mean (SD).
was demonstrated, in the same extent, for both modali-
ties.
We decided to employ HDF and not hemofiltration
alone, in order to control the core temperature. This
could not be done without circulating dialysis water be-
cause the temperature control module (blood tempera-
ture monitor) in the dialysis console operates by means
of a feed back mechanism monitored in the dialysis fluid.
At the same time, we utilized a dose of hemofiltration
in the intervention session (1.20 L/kg/session) that would
have been sufficient if used as predilution hemofiltration
monotherapy. This ensured a strict control of tempera-
ture and similar low molecular Kt/V in both situations.
Interactions between the blood components and the
filter material may theoretically interfere with the hemo-
dynamic parameters. In order to minimize this effect
polysulfone filter material originating from the same
manufacturer in both the treatment modalities was used.
To enhance the differences between hemodialysis and
HDF, with regard to high molecular clearance, low-flux
filters were applied in the hemodialysis group.
Most trials retrieved from the literature used a higher
calcium-ion concentration in the dialysis/substitution
fluid compared with this study. Our intention was to min-
imize hypercalcemia-induced changes during treatment
that may interfere with the vascular reactivity or left ven-
tricular contractility, thereby “sensitizing” our, otherwise,
stable blood pressure population. From a clinical point of
view, none of the participants experienced major side ef-
fects or symptomatic hypotension during the treatments,
despite the fall in mean arterial pressure (10 to 12 mm
Hg). However, it was expected that such a significant drop
in mean arterial pressure would be sufficient to reveal
potential hemodynamic differences between the treat-
ment modalities. However, we cannot exclude a differ-
entiated response if a hypotensive-prone population was
chosen. Regarding the sodium profiles, previous studies
have shown predilution hemofiltration to display an in-
creased sodium accumulation compared with hemodial-
ysis [35]. This was not the case in our study where
the overall sodium loading profiles between the two
treatments were identical; consequently none of the ob-
served differences could be attributed to variable sodium
loading.
Gotch, Keen, and Yarian [36] proposed a theoretic
mechanism of how thermal effects induced by hemodial-
ysis can influence core temperature and blood pressure
stability. During dialysis with ultrafiltration the intra vas-
cular volume reduction may lead to redistribution of
blood from the peripheral circulation. This will reduce
the cutaneous heat exchange and the central tempera-
ture may increase leading to a conflict between vascu-
lar reflexes favoring heat dissipation (with peripheral
vasodilation) and volume conservation (with vasocon-
striction). By keeping the core temperature stable the
above mentioned conflict is prevented, leading to a more
physiologic vascular reactivity and consequently more
physiologic hemodynamic response.
The drop in mean arterial pressure was not fully com-
pensated by an increase in TPR and the pulse rate did not
change significantly in either session in our study. This
was apparently not due to beta blockade as the analy-
sis excluding patients treated with beta blockers showed
the same result. Autonomic uremic neuropathy may be
another possible explanation. The reduction in cardiac
output during both types of treatments appeared to be
due to a fall in stroke volume. The reason for the ob-
served decrease in stroke volume may be the reduction
in relative blood volume and redistribution of the circu-
lating blood volume. The standard clinical chemistry pro-
file was equal in both treatments and could not account
for any potential differences between hemodialysis and
HDF; this was also the case for ultrafiltration volume dur-
ing the sessions.
In our effort to retrieve corresponding studies from
the literature, we discovered numerous studies demon-
strating the stabilizing effect of isolated ultrafiltration,
hemofiltration, or “cool” hemodialyis in blood pressure
[8, 18, 22, 25, 27, 34, 37, 38]. There is also sufficient data
about hemodynamic parameters in postdilution-HDF
procedures [8, 19,28, 39]. On the contrary, research data
regarding high dose on-line pre-HDF have been limited.
When we focused on studies investigating the relationship
between thermal control during dialysis and hemody-
namic consequences, we revealed studies in hemodialysis
[23, 24,34], low-dose postdilution-HDF [28], and hemofil-
tration [25]. Again, experimental data on high-dose, on-
line pre-HDF were lacking.
In a resent study van der Sande et al [27] reached the
same conclusions when they compared hemodialysis and
isolated ultrafiltration. They proposed that the difference
in the extracorporeal energy transfer is the single most
important factor for the observed hemodynamic dispar-
ities between isolated ultrafiltration and hemodialysis.
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They found that vascular reactivity and venous tone im-
proved significantly when the increase in core tempera-
ture was prevented or even more, when core tempera-
ture was decreased. When matching isolated ultrafiltra-
tion with a combination of ultrafiltration + hemodialysis
(at high and low dialysate temperature) for energy trans-
fer, all vascular differences disappeared. Direct compar-
isons with our study are difficult because of the short
session duration (1 hour each). In accordance with this,
Maggiore et al [24] demonstrated a beneficial hemody-
namic effect of blood “cooling” by prevention of the in-
crease in core temperature during dialysis. In a clinical
randomized trial of selected hypotension-prone patients,
they showed that isothermic hemodialysis displayed sig-
nificant less hypotensive episodes compared with ther-
moneutral hemodialysis. The loss of thermal energy, the
decrease of the venous temperature and the drop in sys-
tolic blood pressure and diastolic blood pressure during
isothermic dialysis, was comparable with our findings.
Consistent with these reports, van Kuijk et al [25] con-
firmed the central role of extracorporeal blood tempera-
ture comparing combined ultra filtration + hemodialysis
(dialysate temperature 37.5◦C) with predilution hemofil-
tration (infusate temperature 36 and 39◦C). In agreement
with our results, they found that at equivalent extracor-
poreal blood temperatures, ultrafiltration + hemodial-
ysis and hemofiltration exhibited comparable vascular
(venous tone and vascular resistance) and blood pres-
sure responses. In two other studies designed to compare
the long-term hemodynamic effects of hemofiltration vs.
hemodialysis and HDF, Altieri et al [12, 40] noted a signif-
icant reduction in the frequency of hypotensive episodes
during hemofiltration. Data on temperature change and
energy flux were not reported and that makes direct
comparisons difficult. In one of the few studies com-
paring thermal and hemodynamic parameters between
HDF and hemodialysis, low-dose postdilution-HDF (re-
placement fluid 1 and 2.5 L/hour) was compared against
hemodialyssi (dialysate temperature 35.5 and 37.5◦C).
Likewise, they demonstrated that on the basis of com-
parable energy transfer rates the two modalities display
equivalent hemodynamic profiles[28]. Taking into con-
sideration the design differences, their findings were in
good analogy with ours. Similarly, Donauer et al [19] in-
vestigated 17 dialysis patients with a history of frequent
hypotensive episodes with conventional or temperature
controlled high-flux hemodialysis and postdilution-HDF.
They reported that the rate of intratreatment hypotensive
episodes was identical, between HDF and hemodialysis,
when the temperature of the dialysate was adjusted to
result in identical energy transfer with the correspond-
ing HDF. Despite design differences, the drop in systolic
blood pressure (from 144 ± 27 to 131 ± 25 in HDF
and from 143 ± 28 to 135 ± 27 in hemodialysis) was
in the same range as ours. Movilli et al [41] compared
postdilution-HDF and hemodialysis over 6 months of
treatment in a population of elderly hemodialysis pa-
tients, without matching for energy transfer and dialy-
sis dose. They noted a decrease of hypotensive episodes
from 18% in hemodialysis to 14% in HDF. All three of
the above mentioned postdilution-HDF studies, utilized a
much lower hemofiltration dose compared with our study,
thereby making direct conclusions difficult to draw. An
additional drawback against direct comparisons between
post and predilution techniques is that they display a basic
difference in their “heat-exchange” profiles. In predilu-
tion mode the temperature of the blood returning to the
patient is largely determined by dialysate temperature, as
all fluid returning to the patient comes directly from the
dialyzer. This is not the case in postdilution mode. There
the infusate, originating from the dialysate, returns to the
patient after the filter. Thus, the tubes follow a longer
path thereby an additional “cooling” of the blood occurs
before it returns to the patient.
We provide conclusive evidence that under controlled
conditions hemodialysis and HDF displayed an identical
acute hemodynamic profile. It is most likely that the dis-
parate published data, regarding the hemodynamic dif-
ferences between convective and diffusive dialysis meth-
ods, reflect to some extent confounding factors between
the two treatment modalities. However, it is questionable
if all the observed differences between convective and
diffusive techniques can be attributed only to a simple
phenomenon, as the different thermal profile, especially
on a long-term prospective. Previous long-term studies
have shown that convective methods display better car-
diovascular tolerance and blood pressure behavior [10,
12, 40]. No absolute evidence exists regarding the poten-
tial factors which are responsible for this phenomenon,
but it has been attributed, among others, to the better
removal of high-molecular-weight metabolites and to the
different sodium balance pattern [35], displayed by con-
vective methods compared with diffusive ones. Based on
our acute observations, we can not exclude a long-term
cardiovascular stabilizing effect of convective techniques
over diffusive.
CONCLUSION
We have shown that during temperature controlled,
dialysis dose, and ultrafiltration volume matched condi-
tions the hemodynamic and thermal parameters, between
pre-HDF and low-flux hemodialysis, display a similar pro-
file. An acute beneficial circulatory effect of convective
solute removal over diffusive, could not be demonstrated.
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